gip vs glp-1 The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Simplified summary of the biological
Description
Losing muscle mass compromises physical function and metabolic health
GLP-1 receptor agonists, such as Wegovy, which contain the active ingredient semaglutide, are a class of medications widely used for obesity and type 2 diabetes
Medicare covers GLP-1s for diabetes but not for obesity
Finally, while it is important to stay hydrated, drinking fluids in small amounts, more frequently during the day will avoid bloating and nausea that can come with distension of the stomach
